JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Webinar
How to bring a gene therapy to clinical trials: A case study of a platelet-targeted gene therapy for severe Hemophilia A
In this webinar, we delve into the work behind the study published by Professor Wilcox in NEJM.
Hear how he and his team successfully brought their platelet-targeted gene therapy for severe Hemophilia A to phase 1 trials. He discusses how they overcame key challenges and optimized the manufacturing process.
- The science behind their exciting platelet-targeted gene therapy
- Initial clinical outcomes for the first treated patients
- Key challenges and how the team overcame them to bring the therapy to phase 1 trials
- Best practices for developing gene therapy manufacturing processes
- The crucial role of the LentiBOOST™ transduction enhancer technology in the therapy’s success.
LentiBOOST GMP Grade technology: Not for diagnostic use. Other applications must be authorized by a license from Revvity.
To view the full content please answer a few questions